FDA grants orphan drug designation to LAVA-051 for CLL

Source: Healio News The FDA granted orphan drug designation to LAVA-051 for the treatment of chronic lymphocytic leukemia.LAVA-051 (Lava Therapeutics) is a bispecific antibody that activates the immune system to attack CD1d-expressing cancer cells.Enrollment is...